Definitions of terms used in the survey

Term used in G-FINDER Definition

Amount disbursed^

Funding released to – or goods and services purchased for  a recipient; by extension, the amount already spent. Disbursements record the actual transfer of financial resources, or of goods or services valued at the cost of the funder. It refers only to funding which has already occurred (see Disbursement) and does not include forward scheduled or budgeted transfer of funding, goods or services (see Commitment).

Amount received*

Funding actually transferred to – or goods and services actually purchased for – a recipient. Amount received refers only to outlays that have already occurred (see Disbursement) and does not include the scheduled or budgeted transfer of funding, goods or services to a recipient (see Commitment).


A detailed financial plan of activities and programs expressed in terms of assets, liabilities, revenues and expenses, for a specific period. Budgets are NOT included in the G-FINDER survey.

Calendar year

The twelve-month period from January 1 to December 31, inclusive.


A firm obligation expressed in writing and backed up by the necessary funds, undertaken by a funding organisation to provide specified support to a recipient. Commitment refers to outlays or expected disbursements that have not yet occurred, and are NOT included in the G-FINDER survey.


The unit of account in which funding information is reported, e.g. US Dollar, Euro, UK Pound, etc. Organisations fill in data as per their funding reporting currency.  All financial data is then separately converted to a base currency of $US based on the average annual exchange rate from the IMF average year conversion rate, by Policy Cures Research after the data has been submitted.

Developing countries

Low-and-middle income countries (LMIC). Policy Cures Research uses the World Bank country income classifications to determine groupings. These groupings are reviewed annually and are current as at 1 July of that financial year.  

Direct costs

Actual costs arising from the conduct of a project e.g. salaries, equipment, materials, travel.


The release of funds to – or the purchase of goods or services for – a recipient; by extension, the amount already spent. Disbursements record the actual transfer of financial resources, or of goods or services valued at the cost of the funder. Disbursement refers only to funding which has already occurred.

Emerging infectious disease

For the purposes of the survey, the term emerging infectious disease refers to the list of diseases below, which is based on the priority pathogens identified in the WHO R&D Blueprint. The emerging infectious disease R&D matrix outlines the emerging infectious diseases and products included in the survey, which have been grouped by pathogen family for data collection purposes.

The 2018 survey includes the following emerging infectious diseases: arenaviral haemorrhagic fevers (including Lassa fever); bunyaviral diseases (including Crimean Congo Haemorrhagic Fever (CCHF), Rift Valley Fever (RVF), and Severe Fever with Thrombocytopaenia Syndrome (SFTS)); highly pathogenic coronaviral diseases (including Middle East Respiratory Syndrome coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS)); filoviral diseases (including Ebola and Marburg); henipaviral diseases (including Nipah); and Zika.

Externally funded#

Refers to funding provided to or from another organisation to carry out neglected disease and/or emerging infectious disease R&D activities; sometimes referred to as extramural or external funding.

Financial year#

Recognising that financial year periods often do not match the calendar year and may vary between organisations, for the purposes of the G-FINDER survey, financial year 2017 refers to the financial year occurring predominantly in the year 2017 (e.g. a financial year of April 1, 2017 - March 31, 2018 would be considered as financial year 2017 for this survey). If the financial year runs from July 1 - June 30, then July 1 2016 - June 30 2017 would be considered as financial year 2017.


Transfers made in cash, goods or services for which no repayment is required.

Grant name and/or brief description

The name used by an organisation to identify a grant, or a description of what the grant was directed towards.

Grant number

The code or number used by an organisation to identify a grant.

Indirect costs and overheads

Shared costs, where the cost to the specific project can only be estimated e.g. Human Resources, Finance Division, rental, library.

IMPORTANT: The G-FINDER survey handles these costs differently for public and private sector groups. Public sector groups include overheads if these are part of their grants. Private sector groups exclude overheads, which will be handled separately by the survey.

In-kind contribution*

Contribution of goods and/or services with no payment in money or debt instruments in exchange. May also include transfer of ownership of an asset (other than inventories and cash) or the cancellation of a liability by a creditor, without any counterpart being received in return. Examples include donation of compounds, provision of expertise, or screening conducted without charge.

IMPORTANT: The G-FINDER survey does not include in-kind contributions in the funding tables. However, the final report includes a section highlighting the nature and value of in-kind contributions. If you wish to register your organisation's in-kind contribution, please email

Innovative developing country (IDC)~

Developing country with a relatively sophisticated health biotechnology and government-supported R&D sector (e.g. Brazil, China, Cuba, India and South Africa)

Investment/R&D Investment

Funding, goods and/or services directed toward R&D for neglected or emerging infectious diseases (see also Disbursement).

Key contact#

The individual in an organisation who will complete this survey, or coordinate its completion. The key contact will also act as the primary point of liaison between an organisation and the G-FINDER team.

If the key contact is not the appropriate person, or if the pre-populated key contact details are incorrect, the contact fields can be updated and saved.

Name of funding organisation

The name of the organisation which provided funding to an organisation (if an organisation self-funds its own R&D, this field will be pre-populated with the name of the organisation).

Name of recipient

The name of the organisation that funding was provided to.

Neglected disease

For the purposes of the G-FINDER survey, the term neglected disease refers to diseases that disproportionately affect developing countries, for which new health technologies are needed, and for which there is insufficient commercial market to incentivise private sector R&D investment in developing-country specific product development. The G-FINDER neglected disease R&D Matrix outlines the neglected diseases and products included in the G-FINDER survey.

The 2018 survey includes the following neglected diseases: bacterial pneumonia & meningitis caused by S. pneumoniae or N. meningitides, Buruli ulcer, Chagas’ disease, cholera, cryptococcal meningitis, cryptosporidiosis, dengue, enteroaggregative E.coli (EAggEC), enterotoxigenic E.coli (ETEC), giardiasis, hepatitis C (genotypes 4, 5 & 6), HIV/AIDS, hookworm (ancylostomiasis & necatoriasis), leishmaniasis, leprosy, leptospirosis, lymphatic filarisis (elephantiasis), malaria (P. falciparum and P. vivax), non-typhoidal S. enterica (NTS), onchocerciasis (river blindness), rheumatic fever, rotavirus, roundworm (ascariasis), schistosomiasis (bilharziasis), shigellosis, sleeping sickness, strongyloidiasis & other intestinal roundworms, tapeworm (taeniasis/cysticercosis), trachoma, typhoid and paratyphoid fever (S. typhi and S. paratyphi A), tuberculosis and whipworm (trichuriasis).

Organisation type

The nature of the organisation and the work it carries out.
Academic and other research institutions
Organisations funded by, affiliated with and/or managed by universities or other academic organisations (e.g. Johns Hopkins Malaria Research Institute, Institut Pasteur, Brigham & Women's Hospital).
Government research institutions
Organisations which are funded and/or managed by governments or government agencies (e.g. Australian Army Malaria Institute, Inserm, Japan BCG Laboratory).
Multinational pharmaceutical companies
Pharmaceutical companies with revenues of over $10bn per annum which are privately owned or publicly traded, and conduct their business in many countries (e.g. Pfizer, GSK, Novartis).
Not-for-profit philanthropic foundations, trusts, NGOs, corporate donors#
Not-for-profit trusts, foundations, corporations and individuals (e.g. Bill & Melinda Gates Foundation, Wellcome Trust, Rockefeller Foundation), NGOs and corporate donors.
Product development partnership (PDP)

Although there is no single universally-accepted definition of PDPs, they are typically public health driven, not-for-profit intermediary organisations that use private sector management practices to drive product development in conjunction with external partners. Some PDPs focus on a single disease or product type, while others work across multiple diseases and products, but all share a common goal to develop products that are suitable for developing country use in areas of market failure. While their primary aim is the advancement of public health rather than commercial gain, PDPs generally use industry practices in their R&D activities, for instance portfolio management and industrial project management. Additionally, many PDPs conduct global advocacy to raise awareness of their targeted neglected diseases.

Public sector government#

Governments or government agencies and branches (e.g. DFID, USAID, Brazilian Ministry of Health). Also includes the European Commission.

IMPORTANT: This category is distinct from Government research institutions.

Public sector multilateral#
International organisations that are funded by contributions from member state governments (e.g. World Bank, United Nations agencies such as the World Health Organization).

Public sector pharmaceutical companies
Pharmaceutical companies which are funded by, located within and/or managed by governments or government agencies (e.g. FIOCRUZ).
Small pharmaceutical and biotechnology companies
Pharmaceutical or biotechnology companies with revenues of less than $10bn per annum which are privately owned or publicly traded, and conduct the majority of their business in one country (e.g. Bavarian Nordic, Cellestis, Amyris Biotechnologies).
Organisations which do not fit any of the above definitions.

Phone number

Telephone numbers are entered according to the International Telecommunications Standardisation Sector guidelines: +CC AA PPPP PPPP (C= Country code, A = Area code, and P = Phone number).

R&D role

The role(s) an organisation plays in the field of neglected disease and/or emerging infectious disease research. For example, an organisation may be involved as a funder of neglected disease and/or emerging infectious disease R&D, a fund manager of R&D funding, or as a product developer.


Refers to funding that originates within an organisation for R&D activities carried out by that organisation; sometimes referred to as intramural funding, internal funding or self-funding.

^ Adapted from the OECD DAC Glossary

* Adapted from the OECD Glossary of Statistical Terms

# Adapted from the Malaria R&D Alliance 2005 Global Malaria Funding Survey

Based on the World Bank list of countries

Adapted from the Wellcome Trust

~ Adapted from Hotez et al, 2006, The Neglected Tropical Diseases: The Ancient Afflictions of Stigma and Poverty and the Prospects for their Control and Elimination